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Abstract
Background: It is known that histamine participates in pain modulation. However, the effect of central histamine
on neuropathic pain is not fully understood. Here, we report a critical time window for the analgesic effect of
central histamine in the partial sciatic nerve ligation model of neuropathic pain.
Methods: Neuropathic pain was induced by partial sciatic nerve ligation (PSL) in rats, wild-type (C57BL/6J) mice
and HDC−/− (histidine decarboxylase gene knockout) and IL-1R−/− (interleukin-1 receptor gene knockout) mice.
Histidine, a precursor of histamine that can increase the central histamine levels, was administered intraperitoneally
(i.p.). Histidine decarboxylase (HDC) enzyme inhibitor α-fluoromethylhistidine was administered intracerebroventricularly
(i.c.v.). Histamine H1 receptor antagonist mepyramine and H2 receptor antagonist cimetidine were given intrathecally
(i.t.) and intracisternally (i.c.). Withdrawal thresholds to tactile and heat stimuli were measured with a set of von Frey
hairs and infrared laser, respectively. Immunohistochemistry and Western blot were carried out to evaluate the
morphology of microglia and IL-1β production, respectively.
Results: Histidine (100 mg/kg, i.p.) administered throughout days 0–3, 0–7, or 0–14 postoperatively (PO) alleviated
mechanical allodynia and thermal hyperalgesia in the hindpaw following PSL in rats. Intrathecal histamine reversed
PSL-induced thermal hyperalgesia in a dose-dependent manner and intracisternal histamine alleviated both mechanical
allodynia and thermal hyperalgesia. Moreover, α-fluoromethylhistidine (i.c.v.) abrogated the analgesic effect of histidine.
However, histidine treatment initiated later than the first postoperative day (treatment periods included days 2–3, 4–7,
and 8–14 PO) did not show an analgesic effect. In addition, histidine treatment initiated immediately, but not 3 days
after PSL, inhibited microglial activation and IL-1β upregulation in the lumbar spinal cord, in parallel with its effects on
behavioral hypersensitivity. Moreover, the inhibitory effects on pain hypersensitivity and spinal microglial activation
were absent in HDC−/− mice and IL-1R−/− mice. H1 receptor antagonist mepyramine (200 ng/rat i.t. or i.c.), but not H2
receptor antagonist cimetidine (200, 500 ng/rat i.t. or 500 ng/rat i.c.), blocked the effects of histidine on pain behavior
and spinal microglia.
Conclusions: These results demonstrate that central histamine is analgesic within a critical time window in the PSL
model of neuropathic pain via histamine H1 receptors. This effect may partly relate to the inhibition of microglial
activation and IL-1β production in the spinal cord following nerve injury.
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Background
Neuropathic pain is a significant clinical problem. Typ-
ical manifestations of neuropathic pain, such as thermal
hyperalgesia, mechanical allodynia, and unbearable burn-
ing pain, are lead symptoms of complex regional pain syn-
drome 2 (CRPS-2) [1–3]. Approximately 15 % of sufferers
have unrelenting pain, and overall 30 % of patients who
worked before CRPS-2 onset remain completely unable to
work [4]. Since the pathophysiology of neuropathic pain
in CRPS-2 is still poorly understood, clinical treatment is
largely limited. Intriguingly, however, physical therapy or
medication treatment is clinically much more effective if
started soon after the onset of symptoms, indicating the
significance of early pathophysiological processes and early
intervention for the neuropathic pain of CRPS-2 [5, 6].
Central histaminergic neurons are located in the tubero-
mammillary nucleus of the posterior basal hypothalamus,
and their fibers project widely to different brain regions
and the spinal cord [7]. Previous studies have uncovered
that histamine may participate in pain modulation. It was
reported that a higher dose of histidine, which is the pre-
cursor of histamine and can increase histamine levels in
the central nervous system (CNS) [8–10], but not a lower
dose, suppresses both phases of the pain responses in the
formalin test [11]. Malmberg-Aiello et al. also reported an
antinociceptive effect of peripherally loaded histidine in
paw pressure, abdominal constriction, and hot plate tests
in rats and mice [12]. Moreover, brain histamine was
found to be analgesic in a rat model of acute trigeminal
pain [13]. As for neuropathic pain, Huang et al. found
that, 2 weeks after nerve injury, a low dose of histamine
given intracerebroventricularly (i.c.v.) decreases while a
high dose of histamine increases the nociceptive threshold
to mechanical stimulation [14]. These findings reflect the
acute or transient effect of central histamine on pain sen-
sation in the context of neuropathic pain, but its effect on
the development of neuropathic pain remains unclear. Re-
cently, we reported that central histamine is analgesic in a
rat model of phantom pain, suggesting a potential role of
central histamine in the development of spontaneous
neuropathic pain [15]. We hypothesize that central his-
tamine might be a member among a variety of factors
[16, 17] that are involved in pathophysiological processes
in the CNS following nerve injury and contribute to the
development of neuropathic pain in CRPS-2.
In laboratory studies, models of tibia fracture/cast or
chronic post-ischemia pain have been adopted to recap-
itulate the vascular, trophic, inflammatory, and painful
aspects of CRPS [18, 19]. Based on the association of
CRPS-2 with nerve injury, a partial sciatic nerve ligation
(PSL) model, which has been widely used to induce ex-
perimental neuropathic pain since established by Seltzer
et al. in 1990, has been adopted as an animal model to
mimic the neuropathic pain component of CRPS-2 [20–22].
Therefore, the present study was designed to investigate the
effect of central histamine on pain hypersensitivity in the
hindpaw induced by PSL, looking forward to shedding more




Adult Sprague-Dawley rats (260–300 g, grade II, Certifi-
cate No. SCXK2003-0001, Experimental Animal Center,
Zhejiang Academy of Medical Science, Hangzhou, China),
histidine decarboxylase knockout (HDC−/−) and IL-1 re-
ceptor knockout (IL-1R−/−) mice and their wild-type litter-
mates (C57BL/6J), all male and aged 8–12 weeks, were
used in this study. The rats and mice were kept under a
12-h light-dark cycle (lights on from 08:00 to 20:00).
Water and chow were given ad libitum. All experiments
were in accordance with the Guide for the Care and Use
of Laboratory Animals of the National Academy of Sci-
ences (National Research Council, 1996) and were ap-
proved by the Animal Care and Use Committee of
Zhejiang University. Efforts were made to minimize the
number of animals used and their suffering.
Surgery
Under deep anesthesia with inhalation of isoflurane and
aseptic conditions, the left sciatic nerve was exposed at
high-thigh level and partially ligated as previously de-
scribed [20]. Briefly, the dorsum of the nerve was care-
fully freed from surrounding connective tissues at a site
near the trochanter, just distal to the point at which the
posterior biceps semitendinosus (“PBST”) nerve branches
off the common sciatic nerve. Using honed (no. 5) jew-
elers’ forceps, the nerve was fixed in its place by pinching
the epineurium on its dorsal aspect. A 6-0 silicon-treated
silk suture (8-0 silk suture for mice) was inserted into the
nerve with a 3/8 curved, reversed-cutting mini-needle,
and tightly ligated so that the dorsal 1/3–1/2 of the nerve
thickness was trapped in the ligature. The sciatic nerve in
the sham group was exposed but left intact. The wound
was closed in layers. The animals were then placed back
to their individual cages after recovered from anesthesia in
a warm incubator.
Assessment of PSL-induced pain-like behaviors
Behavioral tests (n = 7–9 animals/group) were carried
out 2–3 h after daily administration of histidine between
11:00 and 17:00, 3 days preoperatively and on days 1, 3,
7, and 14 postoperatively (PO) by blinded examiners.
Animals were placed in a chamber with a mesh metal
floor (20 × 30 cm for the rats and 8 × 8 cm for the mice),
covered by an opaque plastic dome 10-cm high, and
were allowed to habituate for 1 h before tests.
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Withdrawal threshold to tactile stimulation was mea-
sured with a set of von Frey hairs with a bending force ran-
ging from 2.0 to 26.0 g for the rats and from 0.008 to 1.4 g
for the mice. Stimulation was applied to the plantar surface
of the ipsilateral hindpaw. Each hair was indented in the
mid-plantar skin until it just bent. Clear paw withdrawal,
shaking, or licking was considered as a nociception-like re-
sponse. According to Wang et al. [23], the filament of 8 g
was used first for the rats and 0.16 g for the mice. The
stimulation was applied five times (several seconds for each
trial) with an interval of at least 5 min. The strength of the
next filament was decreased if the animal responded or in-
creased if the animal did not respond. The minimum
strength that evoked nociceptive responses at least three
times out of the five trials was considered as the mechanical
withdrawal threshold. Animals that did not respond to all
filaments were given a maximal strength of 26 g for the rats
and 1.4 g for the mice.
Withdrawal threshold to heat stimulation was deter-
mined by beaming a single short pulse of infrared laser
(1.5 mm in diameter, pulse width 200 ms for the rats
and 150 ms for the mice, 14–31 A; LPYE, China) to the
plantar surface of the ipsilateral hindpaw [24]. The laser
was guided by a visible aiming beam, which illuminated
the target with a red spot. The stimulation was applied
three times with an interval of at least 5 min. The
threshold was determined by increasing the current in-
tensity (A) by a step until the withdrawal response was
induced at least two times out of the three trials of
stimulation. The averaged threshold from these three tri-
als was recorded as the thermal nociception threshold.
Determination of histamine concentration in the central
nervous system by high-performance liquid
chromatography
After treated with histidine for 3 days, rats were per-
fused intracardially with PBS (pH 7.4) under anesthesia
by chloral hydrate (400 mg/kg, intraperitoneally (i.p.)).
The spinal cord at L4–L5 and medulla segments was
rapidly removed and stored at −80 °C until assay. Tis-
sues were homogenized with 0.4 mol/l perchloric solu-
tion and centrifuged at 12,000g for 20 min at 4 °C, and
the supernatant was collected. Analysis of histamine was
performed by high-performance liquid chromatography
(HPLC) as described previously [25]. The HPLC was
controlled, the concentration below the minimum de-
tectable level was given a concentration of 10 ng/g, and
the data were acquired and analyzed using Coul Array
software (ESA, Chelmsford, MA, USA). All equipment
was obtained from ESA (Chelmsford, MA, USA).
Immunohistochemistry
Under anesthesia by chloral hydrate, rats and mice were
perfused intracardially with PBS (pH 7.4) followed by
4 % paraformaldehyde. The spinal cord at L4/L5 seg-
ment was dissected and post-fixed in the same fixative
overnight at 4 °C, then cryoprotected by infiltration with
30 % sucrose overnight. Cryostat sections were cut at
16 μm and incubated with 3 % normal donkey serum
(dissolved in PBS) containing 0.3 % Triton X-100 for
2 h, then incubated with rabbit anti-Iba-1 IgG (Wako;
1:1000) overnight at 4 °C and anti-rabbit IgG-Alexa Fluor
488 (Invitrogen; 1:400) for 2 h at room temperature.
Finally, Iba-1 immunostaining was observed by a fluores-
cence microscope (Olympus BX51; Olympus, Tokyo,
Japan), and images were captured under identical illumin-
ation and exposure conditions. The fluorescence intensity
of Iba1 immunoreactivity specifically in the superficial
lamina (I–II) of the dorsal horn from L4 and L5 segments
was measured using Image J software (v1.37, NIH, USA).
The intensity for each section was obtained by averaging
the intensity of five fields that were randomly selected.
The intensity from two to three slides (three to four sec-
tions per slide) was averaged for each animal and then
normalized by that of the sham group.
Western blot analysis
Under chloral hydrate anesthesia, rats were perfused intra-
cardially with PBS. The spinal cord at L4/L5 segment was
rapidly removed and then homogenized and lysed in
homogenization buffer. Protein concentrations were deter-
mined by bicinchoninic acid (BCA) protein assay. After
concentration determination and denaturization, protein
samples were separated by SDS-PAGE gels and then
transferred onto a nitrocellulose membrane. The mem-
branes were incubated with rabbit anti-IL-1β (1:200;
Abcam) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (1:3000; Kang Chen) overnight at 4 °C and
with secondary antibody against rabbit (IRDye 800-
coupled, 1:10,000) for 2 h at room temperature.
Blots were visualized with Odyssey infrared imaging
system (LI-COR Biosciences) and analyzed with the
Odyssey software. The ratio between IL-1β and GAPDH
was calculated and then normalized to the values mea-
sured in the control group.
Drug administration
Rats were weighed and received histidine, the precursor
of histamine, or vehicle postoperatively once daily via in-
traperitoneal injection in various regimens: (1) started
immediately after the surgery and one more injection on
the next day (0–1 day), or three more injections on the
next 3 days (0–3 days), or till day 7 PO (0–7 days), or till
day 14 PO (0–14) and (2) started from 2 days after sur-
gery and one more injection on the next day (2–3 days),
or from day 4 PO and lasting 4 days (4–7 days), or from
day 8 PO and lasting 7 days (8–14 days). Mice were
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given histidine intraperitoneally once daily at a dose of
200 mg/kg during the period of 0–7 days PO.
For intracerebroventricular microinjection (i.c.v.) in rats,
a stainless steel cannula (Reward, China) was implanted
into the left lateral cerebral ventricle (AP −0.96 mm, L
−2.0 mm, V −4.0 mm) and then embedded in the skull
with dental cement 7 days before nerve injury. For intra-
cisternal microinjection, a small burr hole (1~2 mm in
diameter) was drilled in the occipital bone, exposing the
meninges. A small stainless steel cannula (Reward, China)
was carefully implanted (in a caudal direction) along the
internal surface of the occipital bone into the cisterna
magna (depth of 7 mm) [26]. Two hours before histidine
administration, α-fluoromethylhistidine (α-FMH, kindly
provided by Professor C. Kamei, Okayama University,
Japan), 50 μg in 10 μL, was injected once daily in 10 min
through days 0–7 PO via a disposable dental needle (30 G,
Nipro Medical Industries Ltd, Japan), which was attached
to a 15–20-cm PE-10 tube fitted to a 25-μL Hamilton syr-
inge. For intrathecal injection (i.t.), rats were briefly anes-
thetized with isoflurane inhalation, the dorsal fur was
shaved, and the spinal column was arched. A 30-gauge
needle connected to a 10-μL Hamilton syringe was
inserted into the subarachnoid space between the L5 and
L6 vertebrae. Needle penetration into the right place was
indicated by a tail flick. Histamine (50, 100, 200 ng),
mepyramine (100, 200 ng), cimetidine (200, 500 ng), or
IL-1β (10 ng), all in 5 μL, was once daily injected in
10 min through days 0–7 or days 0–3 PO. The dosages
were determined by pilot studies.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was
performed by SPSS for Windows (v 20.0). Statistical sig-
nificance was determined as follows: (1) two-way ANOVA
was used for the comparison of withdrawal thresholds at
different time points and one-way ANOVA followed by
Dunnet’s test for the comparison of the data between
groups (histidine-treated vs saline-treated groups) at the
same time points; (2) unpaired t test was used for the
comparison of Iba-1 fluorescence intensity, IL-1β expres-
sion, and concentration of histamine in the medullar and
lumbar cord (histidine-treated vs saline-treated groups).
The criterion for statistical significance was set at P < 0.05.
Results
Histidine alleviated nerve injury-induced mechanical and
thermal hypersensitivity
Consecutive daily administration of histidine (100 mg/kg,
i.p.) for 3 days did not affect the paw withdrawal thresh-
olds in response to mechanical and heat stimuli in the
sham-operated group (Fig. 1a, b). On day 7 PO, the rats
receiving saline (once daily for 7 days) showed a robust
decrease in withdrawal thresholds to both mechanical
(Fig. 1c) and heat stimuli (Fig. 1d) in the ipsilateral hind-
paw, indicating the development of mechanical allodynia
and heat hyperalgesia. Histidine, once daily for 7 days, did
not show any analgesic effect at the dose of 25 mg/kg
(Fig. 1c, d), while alleviated thermal hyperalgesia at the
dose of 50 mg/kg. By contrast, 100 mg/kg histidine signifi-
cantly inhibited the decrease of withdrawal thresholds to
mechanical and heat stimuli (P < 0.01; Fig. 1c, P < 0.001;
Fig. 1d).
HPLC assay revealed that in naive animals, histamine
content in the medulla was undetectable (below the mini-
mum detectable concentration 10 ng/g) and that in the
lumbar spinal cord was 20 ± 28 ng/g. After 3 days of histi-
dine treatment (100 mg/kg), the contents increased to
120 ± 69 ng/g in the medulla and 165 ± 90 ng/g in the
lumbar spinal cord (Table 1). Moreover, histamine injected
intrathecally once daily during days 0–7 PO at doses of
100 and 200 ng reversed heat hyperalgesia on day 7 PO
but did not affect mechanical allodynia (Fig. 2a, b), while
intracisternal histamine alleviated both mechanical and
thermal hypersensitivity (Fig. 2c, d).
Early initiation of histidine treatment was crucial for its
analgesic effect
We further characterized the analgesic effect of histamine.
It was found that, once histidine treatment through 0–
3 days PO was ceased, the difference in thresholds to
mechanical and thermal stimuli between the saline- and
histidine-treated groups disappeared on day 7 PO, indicat-
ing the absence of outlasting effect (Fig. 3a, b). Moreover,
histidine administered from day 4 till day 7 PO (4–7 days),
when the hypersensitivity had been stably established, was
not able to reduce either mechanical allodynia (Fig. 3a) or
thermal hyperalgesia (Fig. 3b). Furthermore, histidine
treatment from the day of surgery to day 1 PO (0–1 day)
(Fig. 3c and d) or to day 7 PO (0–7 days) (Additional file 1:
Figure S1) significantly alleviated both mechanical allody-
nia and thermal hyperalgesia without outlasting effect.
However, histidine treatment started from day 2 to day 3
PO (2–3 days) (Fig. 3c, d) or from day 8 to day 14 PO (8–
14 days) (Additional file 1: Figure S1) did not alleviate the
hypersensitivity.
Early administration of histidine inhibited nerve
injury-induced spinal microglial activation
It is known that early activation of spinal microglia after
nerve injury plays critical roles in the development of
neuropathic pain. Therefore, we examined the effect of
histidine on activation of spinal microglia following PSL.
There was an increase in Iba-1 immunoreactivity con-
densed in the ipsilateral spinal dorsal horn beginning
from day 1 PO and remaining at least till day 7 PO
(Fig. 4b, e, i), indicating the long-lasting activation of
spinal microglia after nerve injury. This activation was
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suppressed by histidine administered during the period
of 0–1, 0–3, or 0–7 days PO (Fig. 4c, g, j). Administra-
tion of histidine from day 2 to day 3 PO (2–3 days)
inhibited microglial activation (Fig. 4f ), while adminis-
tration from day 4 to day 7 PO (4–7 days) did not show
such effect (Fig. 4l). Microglial activation was still ob-
served on day 7 PO if histidine administration was
stopped on day 3 PO, indicating the absence of an out-
lasting inhibitory effect (Fig. 4k). In addition, intrathecal
histamine during the early phase inhibited spinal microglial
activation in a similar way to systemic loading of histidine
(Additional file 2: Figure S2).
Inhibition of HDC enzyme or knockout of HDC gene
abolished the effects of histidine on pain behavior and
microglial activation
Since histidine cannot be transformed to histamine with-
out HDC enzyme, we introduced the inhibitor of HDC
α-FMH and HDC gene knockout mice (HDC−/−) to fur-
ther verify the effects of histidine are attributed to hista-
mine. Although HDC gene deletion did not affect the
development of either mechanical or heat hypersensitiv-
ity, the analgesic effect (Fig. 5a, b) and inhibitory effect
on spinal microglial activation of histidine were com-
pletely abrogated (Fig. 6a, b). In addition, consecutive
treatment with α-FMH (i.c.v.) for 7 days in the rats re-
sulted in an abolishment of the analgesic effect of histi-
dine (Fig. 5c, d).
Table 1 Histamine concentrations in the medulla and lumbar cord
of rats following intraperitoneal injection of histidine (100 mg/kg)
once daily for 3 days
Groups Medulla (ng/g) Lumbar cord (ng/g)
Saline Not detectable 20 ± 28
Histidine 100 mg/kg i.p. 120 ± 69** 165 ± 90*
*P < 0.05 and **P < 0.01 (the concentration in the medulla of saline-treated
group was designated 10 ng/g, the minimum detectable concentration for our
HPLC method, arbitrarily for comparison between the groups)
Fig. 1 Effects of histidine on thresholds to mechanical and thermal stimuli in rats. Histidine (100 mg/kg, i.p.) administered once daily for three
consecutive days did not affect hindpaw withdrawal thresholds to mechanical and thermal stimuli in naïve and sham-operated rats (a, b). Histidine
treatment for 7 days (0–7 days PO) at various doses (25, 50, or 100 mg/kg, i.p.) alleviated mechanical allodynia (c) and thermal hyperalgesia (d) following
PSL. **P < 0.01 and ***P < 0.001, compared with the vehicle-treated group. ##P < 0.01, compared with the baseline. n = 7–9/group
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Histamine H1 receptor antagonist mepyramine abolished
the analgesic effect and inhibitory effect on microglial
activation of histidine
To clarify the types of histamine receptors involved in
the analgesic effect of histamine, we injected mepyra-
mine (an H1 receptor antagonist) or cimetidine (an H2
receptor antagonist) intrathecally or intracisternally 2 h
after daily histidine administration during 0–7 days PO.
It was found that histidine followed by mepyramine
(200 ng, i.t. or intracisternally (i.c.)) was no longer able
to reduce mechanical allodynia and thermal hyperalgesia
(Fig. 5e–h). Meanwhile, the inhibitory effect of histidine
on microglial activation in the dorsal horn of the lumbar
cord was also abolished by intrathecal mepyramine
(Fig. 6c, d). By contrast, cimetidine (200, 500 ng, i.t. or
500 ng, i.c.) did not influence the analgesic effect of sys-
temic histidine (Fig. 5e–h).
Histidine reduced IL-1β upregulation in the spinal cord
induced by partial sciatic nerve injury
The levels of proinflammatory cytokine IL-1β (the active
form) at different time points (1, 3, and 7 days PO) were
measured to further explore whether the inhibitory effect
of histidine on microglial activation is associated with the
downregulation of microglial function. IL-1β production
increased abruptly and reached its peak within 1 day after
nerve injury and maintained at higher levels than the
sham group through 7 days PO. Histidine treatment sup-
pressed the production of IL-1β in a pattern parallel to
that on microglia activation. That is, histidine initiated
from the day of surgery, regardless for 1, 3, or 7 days or
administered during 2–3 days PO, inhibited IL-1β produc-
tion, but administration during 4–7 days PO did not affect
IL-1β production (Fig. 7a, b).
To verify the involvement of IL-1β inhibition in the
analgesic effect of histidine, we injected IL-1β intra-
thecally 2 h after daily histidine administration for 3 days
and found that histidine was no longer able to alleviate
mechanical allodynia and thermal hyperalgesia (Fig. 7c, d).
Moreover, although the IL-1R−/− mice also developed
hypersensitivity to mechanical and thermal stimuli in
7 days after PSL, the severity was lower and the onset was
delayed compared with the wild-type mice (Fig. 7e, f ). The
inhibitory effects of histamine on behavior and spinal
microglial activation were not observed in the IL-1R−/−
mice (Fig. 7e–h).
Fig. 2 Effects of intrathecal and intracisternal histamine on thresholds to mechanical and thermal stimuli in rats. Histamine injected intrathecally
once daily during days 0–7 PO at doses of 100 and 200 ng reversed heat hyperalgesia following PSL on day 7 PO but did not affect mechanical
allodynia (a, b), while intracisternal histamine alleviated both mechanical and thermal hypersensitivity (c, d). *P < 0.05, **P < 0.01, and ***P < 0.001,
compared with the vehicle-treated group. ##P < 0.01, compared with the baseline. n = 7–9/group
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Discussion
Previously, we found that central histamine is able to
suppress autotomy behavior following peripheral neurec-
tomy in rats, demonstrating the analgesic effect of cen-
tral histamine on the development of phantom pain
[15]. In the present study, we found histidine (0–1, 0–3,
0–7, and 0–14 days, PO) significantly alleviated both
thermal hyperalgesia and mechanical allodynia following
partial sciatic nerve ligation. Moreover, compared with
mechanical allodynia, thermal hyperalgesia appeared
more responsive to histidine, since it was alleviated by a
lower dose of histidine and in a dose-dependent manner
(Fig. 1). Based on the knowledge that systemic histidine
increases the cerebral levels of histamine [8, 9], together
with the following evidence obtained from the present
study, (1) systemic administration of histidine increased
histamine levels in the medulla and lumbar spinal cord;
(2) intrathecal and intracisternal injection of histamine
prevented the development of neuropathic pain; (3) and
inhibition of HDC enzyme or HDC gene knockout, both
of which interrupt the synthesis of histamine from
histidine, abolished the analgesic effect of histidine; and
(4) both intrathecal and intracisternal injection of H1 re-
ceptor antagonist mepyramine antagonized the analgesic
effect of histidine, we conclude that the analgesic effect
of histidine is largely attributed to central histamine.
It is reported that intracerebroventricular pretreatment
with zolantidine (a histamine H2 receptor antagonist),
but not mepyramine, abrogated the anti-hypersensitivity
effect of central histamine in the spinal nerve ligation
(SNL) model of neuropathic pain [27]. The analgesic ef-
fect of central histamine on acute trigeminal pain can be
abolished by intracerebroventricular ranitidine (a hista-
mine H2 receptor antagonist) pretreatment, but not by
chlorpheniramine (a histamine H1 receptor antagonist)
pretreatment [13]. However, our results suggest that
central histamine, via H1 receptors both in spinal and
medullar levels, is able to alleviate neuropathic pain of
CRPS-2 induced by PSL. This conflict implies that anal-
gesic effect of central histamine may involve different re-
ceptor subtypes depending on the sites in the CNS,
although these studies consistently demonstrated the
Fig. 3 Early administration of histidine is crucial for its analgesic effect. Histidine given intraperitoneally once daily through 0–3 days PO or 0–
1 day PO alleviated mechanical allodynia (a, c) and thermal hyperalgesia (b, d) following PSL during the period of treatment, whereas it had no
effect if administered through 4–7 days PO or 2–3 days PO. *P < 0.05, **P < 0.01, compared with the vehicle-treated group. ##P < 0.01, compared
with the baseline. n = 7–9/group
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analgesic effect of central histamine. Another possible
explanation may be that the pathophysiological mecha-
nisms are different between PSL-induced neuropathic
pain and others.
We are interested to find that although histidine re-
duced pain hypersensitivity if given throughout postop-
erative days, it did not show analgesic effect if given
from day 2, 4 (Fig. 3), or 8 PO (Additional file 1: Figure S1).
These results not only indicate that early initiation of his-
tamine is crucial for its analgesic effect on neuropathic
pain in the PSL model of CRPS-2 but imply that central
endogenous histamine may act as an analgesic factor in
pain modulation as well. It has been noted that pain or
sensory abnormalities predominates in acute/early stage of
CRPS [28], and the early and late phases of neuropathic
pain following nerve injury share different pathophysi-
ology and pain networks [29, 30]. Thus, this critical time
window for analgesic effect suggests that histamine may
act on some crucial event(s) that occur in the early phase
of PSL-induced neuropathic pain. Intriguingly, however,
we found that behavioral hypersensitivity relapsed if histi-
dine administration was ceased either on day 2, 4 (Fig. 3),
or 8 PO (Additional file 1: Figure S1). The absence of an
outlasting effect indicates the crucial event(s) that hista-
mine acts on may take place early but tonically be active
at least for 14 days after PSL injury and plays key roles in
the initiation and maintenance of neuropathic pain in
CRPS-2.
Spinal microglial activation occurs during the early
phase of neuropathic pain and has been linked to central
sensitization and initiation of neuropathic pain [31–33].
We found microglial activation in the lumber spinal cord
occurred within 1 day following PSL and lasted for at
least 7 days (Fig. 4), demonstrating the early activation
of spinal microglia. Interestingly, similar to the effect on
behavioral hypersensitivity, histidine treatment initiated
Fig. 4 Effects of histidine on PSL-induced activation of spinal microglia. Photomicrographs show Iba-1 labeling in the lumbar spinal cord on day
1 (a–c), day 3 (e–g), and day 7 PO (i–l). Insets are high-magnification images to demonstrate multidimensional changes of spinal microglia in the
ipsilateral spinal dorsal horn. d, h, and m represent the quantitative analysis of the area occupied by Iba-1-positive cells on day 1, day 3, and day
7 PO, respectively. Histidine (100 mg/kg, i.p.) administered once daily during the period of 0–1, 2–3, 0–3, and 0–7 days PO reduced Iba-1 expression
following PSL. Scale bar = 200 μm (top) and 20 μm (insets). **P < 0.01, ***P < 0.001, compared with the saline-treated group. $P < 0.05, compared with
the indicated groups. n = 3–4/per group
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Fig. 5 (See legend on next page.)
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immediately (0–1, 0–3, and 0–7 days, PO), but not
3 days after PSL, inhibited microglial activation. In
addition to demonstrate the critical role of spinal micro-
glial activation in the development of neuropathic pain
in CRPS-2, these results also provide evidence for the
early phase-specific analgesic effect of central histamine
from the aspect of inhibition of microglial activation.
The findings that histidine concurrently failed to inhibit
microglial activation and behavioral hypersensitivity in
HDC−/− mice (Fig. 6a, b) as well as in mepyramine-
treated rats (Fig. 6c, d) also support that the analgesic ef-
fect of central histamine may relate to the inhibition of
spinal microglia.
Activation of microglia is indicated not only by changes
in morphology but also by the increase in the production
and secretion of various cytokines and chemokines, in-
cluding IL-1β, IL-6, and tumor necrosis factor-a (TNF-α)
[34]. In this study, we found that IL-1β, the functional
index of microglial activation, was upregulated during
7 days PO with a peak at 24 h after PSL. It is very likely
that the prompt IL-1β release in response to nerve injury
contributes to neuropathic pain in the PSL model, as does
in other models [30, 35, 36]. Moreover, histidine flattened
the peak of IL-1β production on day 1 PO and signifi-
cantly inhibited IL-1β expression if administered in a regi-
men that was able to inhibit behavioral hypersensitivity
(See figure on previous page.)
Fig. 5 Blocking histamine synthesis or histamine H1 receptors abolished the analgesic effects of histidine. Histidine (200 mg/kg, i.p.) administered
once daily through 0–7 days PO alleviated hypersensitivity in wild-type mice, but not in HDC−/− mice (a, b). Histidine (100 mg/kg, i.p.) did not
show any analgesic effect if α-FMH (50 μg, i.c.v) was administered simultaneously (c, d). Mepyramine (200 ng/rat, i.t. or i.c.) but not cimetidine
(200, 500 ng/rat, i.t. or i.c.) abolished the analgesic effect of histidine (e–h). *P < 0.05, **P < 0.01, compared with the vehicle-treated group. ##P < 0.01,
compared with the baseline. $P < 0.05, compared with the indicated groups. n = 7–9/group
Fig. 6 HDC gene knockout or H1 receptor antagonist mepyramine abolished the inhibitory effect of histidine on spinal microglial activation.
Histidine (200 mg/kg, i.p.) administered once daily through 0–7 days PO did not inhibit microglial activation in HDC−/− mice (a, b). Mepyramine
(200 ng/rat, i.t.) abolished the inhibitory effect of histidine on microglial activation (c, d). Scale bar = 200 μm (bottom) and 20 μm (insets). ***P < 0.001,
compared with the vehicle-treated group
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Fig. 7 Histidine reduced IL-1β upregulation in the spinal cord induced by PSL. Histidine (100 mg/kg, i.p.) administered once daily during the
period of 0–1, 2–3, 0–3, and 0–7, but not 4–7 days PO, reduced the increase in levels of IL-1β (a, b). Histidine (100 mg/kg, i.p.) did not show any
analgesic effect if IL-1β (10 ng, i.t.) was administered 2 h later (c, d) in 3 days PO. Histidine (200 mg/kg, i.p.) administered through 0–7 days PO
did not affect hypersensitivity and microglial activation following PSL in IL-1R−/− mice (e–h). Scale bar = 200 μm (bottom) and 20 μm (insets). *P < 0.05,
**P < 0.01, and *** P < 0.001 compared with the indicated groups. #P < 0.05, ##P < 0.01, and ###P < 0.001, compared with the baseline. $P < 0.05 and
$$P < 0.01, compared with the indicated groups. n = 7–9/group
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and microglial activation (Fig. 7a, b), but lost its effect on
hypersensitivity or microglial activation in the IL-1β-
treated rats (Fig. 7c, d) and IL-1R−/− mice (Fig. 7e, h)
which express comparable levels of H1 receptors with
their wild-type littermates in the lumbar spinal cord (data
not shown). These results together support the early crit-
ical time window for the analgesic effect of central hista-
mine and the involvement of IL-1β inhibition.
Intriguingly, we also found that inhibition of microglial
activation later than the first day PO does not guarantee
an attenuation of hypersensitivity. That is, the time win-
dow for interrupting microglial activation to prevent
neuropathic pain induced by PSL might be much more
limited than previously identified in other models of
neuropathic pain [30, 32]. Therefore, we propose that, in
order to prevent the development of neuropathic pain in
CRPS-2, intervention aiming to inhibit the activation of
microglia should be initiated immediately after nerve in-
jury. Moreover, our results suggest approaches that can
increase the release of central histamine, such as hista-
mine H3 receptor antagonists, may be options to relieve
neuropathic pain of CRPS-2 in the very early phase but
may not benefit patients with established CRPS-2, al-
though an acute robust increase of central histamine has
been reported to ameliorate allodynia following PSL
[14]. On the other hand, the first-generation H1 receptor
antagonists that have permeability to the CNS should be
avoided in patients with this disease because they poten-
tially neutralize the analgesic effect of central histamine.
In addition, it has been reported that an early inhib-
ition of microglial activation can attenuate hypersensitiv-
ity following nerve injury [37, 38]. To our surprise,
however, the present study found that although histidine
administered on the second and third days PO (2-3 days,
PO) suppressed microglial activation as well as IL-1β
production, it had no effect on pain hypersensitivity
(Fig. 4f, h). These findings are supportive to the studies
that reported the disassociation between microglial in-
hibition (indicated by microglial markers such as Iba1)
and analgesic outcomes [39–41]. This finding also im-
plies that the hypersensitivity later than 1 day after PSL
may not solely depend on microglial activation. More-
over, since histidine administered during days 4–7 PO
did not inhibit microglial activation (Fig. 4l, m), we
speculate that histamine presumably acts on some early
event(s), which occurs soon after PSL injury and triggers
the activation of microglia, but not directly on microglia.
This speculation is partially supported by the recent
finding that only a very little percentage (less than 10 %)
of microglia from the brain responds to histamine [42].
Unlike systemic histidine, intrathecal injection of his-
tamine abolished thermal hyperalgesia, but had no effect
on mechanical allodynia following PSL. Since histamine
levels are increased all over the CNS by systemic histidine,
but increased only locally in lower segments of the spinal
cord by intrathecal histamine, it seems that histamine re-
ceptors in supraspinal structures may be involved in the
anti-allodynic effect of histidine. This was supported by
the finding that intracisternal injection of histamine allevi-
ated both mechanical allodynia and thermal hyperalgesia
(Fig. 2c and d). Moreover, intracisternal injection of H1 re-
ceptor antagonist mepyramine, rather than H2 receptor
antagonist cimetidine, antagonized the analgesic effect of
systemic histidine (Fig. 5g, h). These results may imply
that pathophysiological changes in the spinal level follow-
ing partial sciatic nerve injury are more associated with
thermal hyperalgesia, while those in supraspinal level are
associated with mechanical allodynia in addition to ther-
mal hyperalgesia. This speculation is partially supported
by the previous studies reporting that ascending input to
nucleus gracilis is critical to the manifestation of tactile
allodynia [43–45]. Therefore, it is possible that histamine
may inhibit both mechanical allodynia and thermal hyper-
algesia of CRPS-2 through acting on H1 receptors at the
supraspinal levels.
Conclusions
The present study found that central histamine via spinal
and supraspinal H1 receptors alleviates neuropathic pain
in the early phase of CRPS-2 induced by partial nerve in-
jury in rodents. The coincident inhibition of spinal micro-
glial activation and IL-1β upregulation early after nerve
injury may contribute to this effect. These results suggest
that intervention approaches should be initiated as early
as possible for the treatment of neuropathic pain compo-
nent of CRPS-2, while CNS-penetrating H1 receptor an-
tagonists should be avoided.
Additional files
Additional file 1: Figure S1. Effects of histidine administered in other
regimens on mechanical allodynia (A) and thermal hyperalgesia (B) following
PSL in rats. Histidine (100 mg/kg, i.p.) or saline was administered once daily
during the period of 0–14 days PO, 0–7 days PO, or 8–14 days PO. *P< 0.05,
**P < 0.01, and ***P< 0.001, compared with the saline-treated group. #P<
0.05, ##P < 0.01, compared with the baseline. n = 7–9/group. (TIF 1,201 kb)
Additional file 2: Figure S2. Effect of intrathecal histamine (HA) on
PSL-induced activation of spinal microglia. Histamine (200 ng/rat, i.t.) on
the first day PO (0–1 day) (B) or 2–3 days PO (2–3 days) (E) reduced Iba-1
expression following PSL. C and F represent the quantitative analysis of
the area occupied by Iba-1-positive cells on day 1 and day 3 PO, respectively.
Scale bar = 200 μm (top) and 20 μm (insets). **P< 0.01, compared with the
saline-treated group. n= 3–4/per group. (TIF 2,148 kb)
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